Reneo Pharmaceuticals, Inc. (RPHM): Price and Financial Metrics
RPHM Price/Volume Stats
| Current price | $1.66 | 52-week high | $10.98 |
| Prev. close | $1.68 | 52-week low | $0.98 |
| Day low | $1.62 | Volume | 65,076 |
| Day high | $1.68 | Avg. volume | 272,243 |
| 50-day MA | $1.67 | Dividend yield | N/A |
| 200-day MA | $4.57 | Market Cap | 55.48M |
RPHM Stock Price Chart Interactive Chart >
Reneo Pharmaceuticals, Inc. (RPHM) Company Bio
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Latest RPHM News From Around the Web
Below are the latest news stories about RENEO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RPHM as an investment opportunity.
These Stocks under $10 Are Poised To ExplodeIn this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […] |
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder StudyReneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%. |
Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today?Reneo Pharmaceuticals Inc (NASDAQ: RPHM) shares are sinking after the company released data from its pivotal STRIDE Phase 2b study of mavodelpar in adult patients with primary mitochondrial myopathies (PMM), a group of mitochondrial diseases that cause prominent muscular problems. The study did not meet its primary efficacy or secondary efficacy endpoint. The trial's primary efficacy endpoint was the change from baseline in the distance walked during the 12-minute walk test (12MWT) at week 24. T |
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its pivotal STRIDE study (NCT04535609) of mavodelpar in adult patients with primary mitochond |
Reneo Pharmaceuticals Inc (RPHM) Reports Q3 2023 Financial ResultsAnticipation Builds for STRIDE Study Results as R&D Expenses Climb |
RPHM Price Returns
| 1-mo | 0.61% |
| 3-mo | 0.61% |
| 6-mo | -79.25% |
| 1-year | -83.35% |
| 3-year | -87.60% |
| 5-year | N/A |
| YTD | 3.75% |
| 2023 | -31.33% |
| 2022 | -72.75% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...